MARKET INSIGHTS
Global (R)-1-Aminoindane (CAS 10277-74-4) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.
(R)-1-Aminoindane is a chiral amine compound derived from indane, characterized by its single stereocenter that confers the (R)-configuration. It serves as a critical chiral building block and pharmaceutical intermediate, widely utilized in the synthesis of enantiomerically pure active pharmaceutical ingredients (APIs). The compound finds notable application in the development of neurological drugs, including selective monoamine oxidase inhibitors (MAOIs), and has been integral to the synthesis of rasagiline, a well-established treatment for Parkinson’s disease.
Global market is gaining steady momentum, primarily driven by the rising global burden of neurodegenerative disorders and the pharmaceutical industry’s increasing emphasis on chiral synthesis and stereochemically pure compounds. Furthermore, growing investments in asymmetric synthesis research and the expanding pipeline of CNS-targeted therapeutics are reinforcing demand. Key specialty chemical manufacturers and fine chemical producers, including those operating across North America, Europe, and Asia-Pacific, are actively scaling production capabilities to meet rising pharmaceutical-grade requirements for this compound.
(R)-1-Aminoindane (CAS 10277-74-4) Market – View in Detailed Research Report
🔟 1. Hairui Fine Chemicals Co., Ltd.
Headquarters: Shanghai, China
Key Offering: Pharmaceutical‑grade (R)-1‑Aminoindane, custom synthesis services
Hairui Fine Chemicals has established itself as a leading supplier of chiral intermediates for the neurology sector, providing high‑purity (≥99%) (R)-1‑Aminoindane used in rasagiline and other MAO‑B inhibitors. The company leverages advanced asymmetric hydrogenation and biocatalytic resolution to achieve high enantiomeric excess, ensuring compliance with global pharmacopeia standards.
Sustainability & Growth Initiatives: Investment in green hydrogenation, waste‑reduction protocols, and continuous‑flow manufacturing to enhance yield and reduce solvent usage.
- Scale‑up of high‑purity production lines for API manufacturers
- Partnerships with major pharma R&D labs for custom chiral routes
- Commitment to ISO 9001 and ISO 14001 certifications
9️⃣ 2. Biosynth AG
Headquarters: Basel, Switzerland
Key Offering: High‑purity (R)-1‑Aminoindane, cGMP compliant manufacturing
Biosynth AG is renowned for its precision synthesis of chiral intermediates for CNS therapeutics. The company’s state‑of‑the‑art facilities produce (R)-1‑Aminoindane with enantiomeric excess >99.5%, supporting the development of rasagiline and emerging MAO‑B inhibitors.
Sustainability & Growth Initiatives: Integration of renewable energy sources in production, implementation of closed‑loop solvent recovery, and continuous improvement of process economics.
- Expansion of European manufacturing footprint
- Collaboration with academic institutions on asymmetric catalysis
- Development of proprietary chiral ligands for improved selectivity
8️⃣ 3. Capot Chemical Co., Ltd.
Headquarters: Beijing, China
Key Offering: Research‑grade (R)-1‑Aminoindane, rapid custom synthesis
Capot Chemical specializes in providing flexible supply of (R)-1‑Aminoindane for research and early‑stage development. Its scalable synthetic routes allow rapid turnaround for academic and industrial partners.
Sustainability & Growth Initiatives: Adoption of solvent‑free synthesis methods and use of biodegradable catalysts to reduce environmental impact.
- Rapid response manufacturing for emerging therapeutic candidates
- Strategic alliances with contract research organizations (CROs)
- Investment in process analytics and quality assurance
7️⃣ 4. Enamine LLC
Headquarters: Kyiv, Ukraine
Key Offering: Custom chiral synthesis, API intermediates for CNS drugs
Enamine LLC offers bespoke synthesis of (R)-1‑Aminoindane, supporting pharmaceutical companies in developing next‑generation MAO‑B inhibitors and other neuroactive compounds. The company’s expertise in asymmetric catalysis and biocatalysis drives high purity and yield.
Sustainability & Growth Initiatives: Implementation of green chemistry principles, reduction of hazardous reagents, and continuous‑flow technology.
- Expansion of custom synthesis portfolio
- Collaboration with biotech startups for novel therapeutic platforms
- Development of modular synthesis modules for rapid scale‑up
6️⃣ 5. Achieve Chemicals Ltd.
Headquarters: Guangzhou, China
Key Offering: Technical‑grade (R)-1‑Aminoindane, bulk supply for API production
Achieve Chemicals delivers high‑volume, cost‑effective (R)-1‑Aminoindane to generic manufacturers. Their optimized hydrogenation process achieves >95% yield with minimal waste.
Sustainability & Growth Initiatives: Focus on energy efficiency, waste minimization, and use of renewable feedstocks.
- Scaling of bulk production lines for emerging markets
- Partnerships with Asian CMOs to support regional demand
- Implementation of advanced process monitoring systems
5️⃣ 6. Apollo Scientific Ltd.
Headquarters: London, United Kingdom
Key Offering: High‑purity (R)-1‑Aminoindane, custom synthesis for research and industrial clients
Apollo Scientific provides tailored synthesis solutions for pharmaceutical developers, ensuring stringent chiral purity and compliance with cGMP standards.
Sustainability & Growth Initiatives: Adoption of biocatalytic routes and solvent‑free processes to reduce carbon footprint.
- Collaboration with academic research groups on asymmetric synthesis
- Development of scalable biocatalytic platforms
- Investment in digital process control and analytics
4️⃣ 7. JTD Chemicals Co., Ltd.
Headquarters: Shenzhen, China
Key Offering: Research‑grade (R)-1‑Aminoindane, rapid synthesis for early‑stage projects
JTD Chemicals focuses on fast turnaround synthesis for biotech and pharma companies, providing high‑purity intermediates with flexible delivery schedules.
Sustainability & Growth Initiatives: Implementation of energy‑efficient reactors and waste‑reduction protocols.
- Rapid scale‑up capabilities for emerging therapeutic candidates
- Strategic partnerships with contract manufacturing organizations (CMOs)
- Continuous improvement of process yield and cost efficiency
3️⃣ 8. TCI Chemicals
Headquarters: Tokyo, Japan
Key Offering: Technical‑grade (R)-1‑Aminoindane, bulk supply for API production
TCI Chemicals delivers high‑volume (R)-1‑Aminoindane to generic and branded manufacturers, utilizing efficient hydrogenation and resolution techniques to maintain quality.
Sustainability & Growth Initiatives: Focus on green chemistry, renewable energy use, and waste minimization.
- Expansion of production capacity in Asia‑Pacific
- Collaboration with regional CMOs for supply chain resilience
- Investment in continuous‑flow manufacturing technology
2️⃣ 9. Finetech Industry Limited
Headquarters: Hong Kong, China
Key Offering: Custom synthesis of (R)-1‑Aminoindane, high‑purity intermediates for API developers
Finetech Industry provides bespoke synthesis solutions, enabling pharmaceutical companies to access high‑purity chiral intermediates with rapid lead times.
Sustainability & Growth Initiatives: Implementation of green solvents, energy‑efficient reactors, and process optimization.
- Rapid scale‑up for emerging therapeutic pipelines
- Strategic alliances with global pharma and biotech firms
- Continuous improvement of process economics and sustainability metrics
1️⃣ 10. Symone Chemicals
Headquarters: New Delhi, India
Key Offering: Technical‑grade (R)-1‑Aminoindane, bulk supply for API manufacturers
Symone Chemicals supplies cost‑effective (R)-1‑Aminoindane to generic manufacturers in India and beyond, supporting the growing local pharmaceutical industry.
Sustainability & Growth Initiatives: Focus on renewable energy integration, waste recycling, and process efficiency.
- Expansion of production facilities in India
- Partnerships with Indian CMOs to meet domestic demand
- Investment in green chemistry and energy‑saving technologies
Download FREE Sample Report: (R)-1-Aminoindane (CAS 10277-74-4) Market – View in Detailed Research Report
Get Full Report: (R)-1-Aminoindane (CAS 10277-74-4) Market – View in Detailed Research Report
🌍 Outlook: The Future of (R)-1‑Aminoindane Market
The (R)-1‑Aminoindane market is poised for robust growth driven by the expanding pipeline of CNS therapeutics and the increasing demand for enantiomerically pure APIs. Key drivers include:
- Rising prevalence of neurodegenerative disorders such as Parkinson’s and Alzheimer’s
- Advancements in asymmetric synthesis and biocatalysis reducing cost and improving yield
- Growing investment in contract manufacturing and global supply chain resilience
- Regulatory emphasis on chiral purity and sustainability in pharmaceutical manufacturing
Geographically, Asia‑Pacific is expected to lead growth at a CAGR of 12% through 2030, while North America and Europe will continue to dominate as major consumers of high‑purity intermediates.
📈 Future Trends Shaping the Market
- Continuous‑flow manufacturing becoming the industry standard for chiral intermediates, enabling faster scale‑up and higher product quality
- Integration of AI‑driven process optimization to reduce waste and improve energy efficiency
- Expansion of biocatalytic routes for (R)-1‑Aminoindane, offering lower environmental impact and cost savings
- Increasing focus on personalized medicine, driving demand for enantiopure APIs and boosting the role of (R)-1‑Aminoindane as a critical building block
- Top 10 Companies in the Liquid Alloy Market (2026): Market Leaders Powering Global Innovation - June 2, 2026
- Top 10 Companies in the Global Antazoline Market (2026): Market Leaders Driving Allergy Relief - June 2, 2026
- Top 10 Companies in the Topcoats for Aerospace Coatings Market (2034): Market Leaders Powering Global Aviation - June 2, 2026